Related Experiment Video
Updated: Nov 11, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Abstract:
A reversible BTK inhibitor, pirtobrutinib, could be effective for patients with B-cell malignancies whose disease has worsened on other targeted therapies or who cannot tolerate the toxicity of irreversible BTK inhibitors. In a phase I/II trial, patients previously treated with other BTK inhibitors had an overall response rate of 62% to pirtobrutinib.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...